- Products & Services
- Knowledge Base
ATLANTA, GA, May 16, 2017 /24-7PressRelease/ -- The MNG Healthy Exome from MNG Labs is an innovative new screening test that will offer healthy individuals a comprehensive overview of their genetic makeup. The MNG Healthy Exome provides whole exome sequencing and copy number assessment for advanced screening for individuals who wish to know their carrier status or predisposition to severe genetic disorders. The new test is capable of determining an individual's carrier status for over 5,000 known pathogenic variants associated with severe heritable disorders and/or predisposition to develop specific types of cardiac disorders (e.g. arrhythmias and heart failure), cancers (e.g. colon, prostate, breast and ovarian) and/or neurodegenerative disorders such as Parkinson's and various dementias. This test is intended for asymptomatic individuals who want to use this information for family planning, preventing the development of life threatening diseases or aid with their early detection.
"This is a groundbreaking and exciting approach to the genetic screening market. The MNG Healthy Exome marks an important product development success for MNG as we expand our product lines," explains Terry Conrad, Chief Executive Officer of MNG Laboratories. "We are a leading neurogenetic laboratory committed to delivering answers no one else can and our MNG Healthy Exome complements our proven line up of NGS Panels and well recognized neurochemical tests."
"The MNG Healthy Exome is a testament to the commitment of our lab team to offer innovation and flexibility to help prevent fatal, severe, untreatable, difficult to manage genetic disorders," noted Peter L. Nagy, Chief Medical Officer of MNG Laboratories. "This supports our goal to deliver the quality answers our customers expect to help improve their patient's quality of life."
In addition to the unique MNG Healthy Exome, MNG Laboratories launched the first ever carrier screening exome, the MNG Carrier Exome and has recently improved turnaround times to 4 weeks or less for their NGS panels. MNG has recently revamped their lineup of epilepsy and muscular dystrophy panels, capturing more pathogenic variants than ever before. Additional panel updates and a robust plan of new products is planned throughout 2017.
About MNG Laboratories
MNG Laboratories is a leading provider of neurogenetic testing through clinical services, complex biochemical testing and sequencing. Our extensive offering of Next Generation Sequencing panels is recognized by genetic experts around the world. Combined with our validated proprietary Genome MaNaGer database and variant calling methods, our Neurogenetic Answers platform delivers first-in-class reporting and fast turnaround times. We specialize in cellular energetics defects, muscular dystrophies, epilepsy, intellectual disabilities, movement disorders and cardiomyopathy. Powered by a culture of discovery and advancement, MNG Laboratories seeks to make a difference for clients.
More information about MNG Laboratories can be found at www.mnglabs.com.
# # #